Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer： a Single-arm, Multicenter， Prospective Phase II Study

NCT04572542 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Xiamen University as lead sponsor.

NCT NCT04572542
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04572542 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer： a Single-arm, Multicenter， Prospective Phase II Study
Lead sponsor
The First Affiliated Hospital of Xiamen University
Phase
Phase 1/2
Overall status
Unknown status
Start date
January 1, 2020
Completion date
June 1, 2022
Enrollment
46 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced or metastatic gastric adenocarcinoma